These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 782701)

  • 21. Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple myeloma.
    Presant CA; Klahr C
    Cancer; 1978 Sep; 42(3):1222-7. PubMed ID: 698913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [On the therapy of lymphogranuloma. CCNU (1(2-chlorethyl)-3-cyclohexyl-1-nitrosourea) and BCNU (1,3-bis(2-chlorethyl)-1-nitrosourea) as well as BCNU combinations in Hodgkin's lymphogranuloma, stage 3 and 4].
    Brunner KW; Maurice P; Sonntag RW
    Schweiz Med Wochenschr; 1972 Oct; 102(43):1546-51. PubMed ID: 4647016
    [No Abstract]   [Full Text] [Related]  

  • 23. Combination chemotherapy MOCCA in resistant and relapsing multiple myeloma. Finnish Leukaemia Group.
    Eur J Haematol; 1992 Jan; 48(1):37-40. PubMed ID: 1730278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma.
    Broun GO; Petruska PJ; Hiramoto RN; Cohen HJ
    Cancer Treat Rep; 1982 Feb; 66(2):237-42. PubMed ID: 7034931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination therapy for multiple myeloma.
    Alexanian R; Salmon S; Bonnet J; Gehan E; Haut A; Weick J
    Cancer; 1977 Dec; 40(6):2765-71. PubMed ID: 589554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of myeloma maintenance regimen of prednisone. Adriamycin, imuran, and vincristine in a murine plasmacytoma model.
    Ghanta VK; Cohen HJ; Silberman HR; Durant JR; Hiramoto RN
    Cancer Clin Trials; 1981; 4(2):135-41. PubMed ID: 7249251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The nitrosoureas: carmustine (BCNU) and lomustine (CCNU).
    Weiss RB; Issell BF
    Cancer Treat Rev; 1982 Dec; 9(4):313-30. PubMed ID: 6762924
    [No Abstract]   [Full Text] [Related]  

  • 28. Nitrosoureas: useful agents for the treatment of advanced gastrointestinal cancer.
    Douglass HO; Lavin PT; Moertel CG
    Cancer Treat Rep; 1976 Jun; 60(6):769-80. PubMed ID: 782699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Recent therapy for refractory myeloma].
    Togawa A
    Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug - resistant multiple myeloma. A trial with the M 2 cyclic alkylating agent polychemotherapy.
    Buonanno G; Tortarolo M; Valente A; Castaldo C; Russolillo S; Gonnella F
    Haematologica; 1978 Feb; 63(1):45-55. PubMed ID: 417971
    [No Abstract]   [Full Text] [Related]  

  • 31. Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study.
    Alberts DS; Salmon SE
    Cancer Chemother Rep; 1975; 59(2 Pt 1):345-50. PubMed ID: 1097093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. alpha-Interferon for remission maintenance: preliminary report on the Southwest Oncology Group Study.
    Salmon SE; Beckord J; Pugh RP; Barlogie B; Crowley J
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):33-6. PubMed ID: 1948127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
    Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L
    Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265
    [No Abstract]   [Full Text] [Related]  

  • 34. Aggressive combination chemotherapy in multiple myeloma. A multicentre trial. Finnish Leukaemia Group.
    Scand J Haematol; 1985 Aug; 35(2):205-9. PubMed ID: 3901244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of plasma cell myeloma with cytotoxic agents.
    Bergsagel DE; Pruzanski W
    Arch Intern Med; 1975 Jan; 135(1):172-6. PubMed ID: 803363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Combination chemotherapy of multiple myeloma].
    Uzuka Y; Saito Y; Ito T
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1481-7. PubMed ID: 2389944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.
    Durie BG; Dixon DO; Carter S; Stephens R; Rivkin S; Bonnet J; Salmon SE; Dabich L; Files JC; Costanzi JJ
    J Clin Oncol; 1986 Aug; 4(8):1227-37. PubMed ID: 3525768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of recurrent lymphomas with vincristine, BCNU, doxorubicin, and prednisone (VBAP): a Southwest Oncology Group Study.
    Weick JK; Jones SE; Haut A; Fisher R; Dixon D
    Cancer Treat Rep; 1981; 65(7-8):611-4. PubMed ID: 6166373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.